FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 02/2024”.
The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of February 2025 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 2,537m (+43% vs. 2024)
- Biotech/Pharma received 42% of the total investment volume (EUR 1,059m) with metabolic disorders (including Diabetes, Obesity) being the leading indication (37%)
- In February, Augustine Therapeutics (Belgium) secured the highest transaction volume with EUR 37m, followed by Avelios Medical (Germany) with EUR 30m and Germitec (France) with EUR 29m
- Addendum from January 2025: In January, there was a Series A financing round of EUR 395m for Verdiva Bio (United Kingdom) – the biggest early-stage financing round Europe has ever seen within BioTech
- Forbion (Netherlands) is the most active investor (by deal volume in 2025), followed by OrbiMed (United States) and BDT & MSD Partners (United States)
To access the full report, please click here.